Condition
Leukemia|Lung Cancer|Malignant Mesothelioma|Myelodysplastic Syndromes|Primary Peritoneal Cavity Cancer
Estimated Enrollment: 22
Age Group: 18 Years to 120 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: 06-085|P30CA008748|P01CA023766|MSKCC-06085
Study First Received: November 9, 2006
Last Updated: February 2, 2016
Estimated Primary Completion Date: June 2009
Primary Outcome Measures:
Safety|Immune Response
Sponsors and Collaborators:
Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Innovive Pharmaceuticals
Website Link: https://ClinicalTrials.gov/show/NCT00398138
